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Abstract
Pharmacogenetics of auto-immune diseases is a complex field of application for this relatively new discipline, since we still have a partial
knowledge of the biological mechanisms of the disease and of the drugs currently used to treat it. We address a few key issues that emerge when
planning a pharmacogenetic investigation in Multiple Sclerosis and that relate to the complexities existing at the biological-genetic level and at
the phenotypic characterization.
In fact, we think that a clearer characterization of the clinical phenotype representing the end-point of the investigation together with a critical
appraisal of the multi-faceted dimension of the genetic component of either the disease and the pharmacogenetic profile of the drug investigated,
will help to design more thorough study and to achieve deeper understanding of the practical results. We will primarily focus our research con-
siderations on the role of Interferon Beta (IFN-b) as a prototypal therapeutic agent in Multiple Sclerosis.
 2005 Elsevier Ltd. All rights reserved.
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Pharmacogenetics is a relatively new area of medical genet-
ics, which focus on the identification and study of the genetic
mechanisms involved in controlling both the individual re-
sponse of a patient to a given medication and the emergence
of adverse effects related to a given medication. Pharmacoge-
netics is rapidly progressing in all areas where the knowledge
of the biology of a disease is well established and/or for those
drugs that have a well-known mechanism of action at the cel-
lular level, like those used in the treatment of some forms of
cancer.
However, for autoimmune disorders, and specifically for
Multiple Sclerosis (MS), the situation is quite different, since
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of the disease and of the drugs currently used to treat it.
Multiple Sclerosis (MS) is a disorder of the central nervous
system with an inflammatory and a neurodegenerative compo-
nent, and is characterized by a variable clinical pattern, which
ultimately leads to a progressive neurological dysfunction. MS
can present either as a recurrent disorder where acute phases
are interspersed with even long periods of quiescence (Relaps-
ing-Remitting, RR) or as a progressive disorder from the be-
ginning without relapses (Primary Progressive, PP) [1]. The
relapsing-remitting form is proportionally more frequent in
younger patients and in females, but both forms of the disease
ultimately lead to a deficit state with a variable degree of dis-
ability. Recent revisions of the classification of MS emphasize
a neurodegenerative component characterized by axonal loss,
which occurs from the early phases of the disease [2] and is
considered responsible of the long-term irreversible disability:
the neurodegenerative component thus can be interpreted as
a consequence of the inflammatory-immune process or as an
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plays a major role in the development of the disease, even
though a still unknown non-genetic component, probably of
viral origin, has also a key causal role. Whatever the complex-
ity of the etiology, however, the difficult interplay of the bio-
logical-genetic component is critically relevant, since our
current abilities to treat the disease occur at this level. Unfor-
tunately, we do not yet have a definitive therapy for MS:
among the existing treatments, Interferons-beta-1a and -1b
(IFN-b) have been shown to decrease clinical relapses, poten-
tially decrease brain disease events and also slow the progres-
sive disability [3]. However, even for IFN-b, the effect of
therapy is only partial and a consistent number of patients
are considered poor or no-responder to the treatment: a pivotal
issue is that we still do not know how and why IFN-b works in
definitively treating some patients, while it fails to be effective
in other subjects; the solution to this issue is extremely rele-
vant, since it could help us to design more powerful drugs to
treat the disease. The only published reports that have ad-
dressed this topic looked at several polymorphisms in the
IFN-b receptor genes (IFNAR1 and IFNAR2) [4,5] and in the
promoter region of the IL-10 gene [6], but overall no clear sig-
nificant differences in the genetic makeup of these genes have
been found between patients responder or non-responder to the
therapy. This preliminary result suggests to re-evaluate and
re-think our general strategy in performing pharmacogenetic
studies of MS, pointing to two major sources of complexity,
that is the clinical dimension of the responder/non-responder
phenotype and the multi-faceted component of the genetic
mechanism where the effect is most probably due to the joint
role of several rather than just one or two genes.
2. Genetic bases of the pharmacogenetics of MS
As in the majority of pharmacogenetics traits and most no-
tably in complex diseases, a set of genes that belong to two
major domains, the metabolism of the drug and the mechanism
specifically responsible for the medication effect, jointly influ-
ence the effect of the treatment. While the genetic control of
the metabolism of small molecules is well known, we still
do not yet have a definitive and clear knowledge of the metab-
olism of a protein drug as in MS. Nonetheless, the proper
functioning of the complex metabolism and breakdown of,
say, IFN-b, will undoubtedly and markedly affect the ultimate
outcome of the treatment of MS. At a relatively simple level,
we can imagine that the inability to properly metabolize IFN-
b could contribute to the development of adverse effects on
one side, hence the need to suspend the treatment, and to
the inability of carrying a response at the other extreme level.
In any case, even when the drug does not have difficulties in
eliciting a response at the target level, a genetic flaw at the
metabolic level could thwart its therapeutic effect: despite
the relevance of the topic, there are no published studies ad-
dressing this issue. When we consider the pharmacodynamic
component of the drug, we face additional problems. First, it
is probably limiting to focus only on the effect of polymor-
phisms at one gene: expanding the example of the currenttherapy of MS, we know that IFN-b is involved in at least
three different pathways, one regulating the Cytokines (CK),
enhancing IL10 and inhibiting IL12 secretion [7,8], a second
related to the effect of Toll-like receptors [9], and finally the
JAK-STAT pathway [10,11]. A detailed review of these path-
ways would require a lengthy appraisal of these systems, but
here we want just to point up a few considerations. The
Toll-like receptor signaling pathway includes more than 60
genes and, among others, IFN-b seems implicated in T-cells
stimulation and, even more directly, in controlling for antiviral
effects, which may represent an interesting link between the
genetic component and the proposed trigger effect of a virus
in the emergence of the disease [9]. Via the cytokine receptor
system, the IFN-b is also part of the JAK-STAT signaling path-
way, composed by more than 20 major genes, with a role in
growth, proliferation and immunity mediated by the STAT
proteins and CBP through the IFN-receptors IFNRA1 and 2.
These two pathways are very interesting for their role in the
evolution of the immune system, most notably the Toll-like
receptor pathway, and for the signaling in response to IFN-
inducible genes, modulating or altering biological responses:
if some current hypotheses showing a more direct relation of
IFN-b with STAT5 are correct, it should be remembered that
STAT5 knockout mice exhibit defects in T-cell (and NK
cell) proliferation, thus suggesting a pathogenetic correlation
with some hypothesis related to the immune dysfunction in
MS. Among the three, the Cytokine (CK) pathway is surely
the most complex of all and there already are excellent reviews
that describe the role of IFN-b within the CK pathway. Here,
in addition to the well known role of the cytokines in inflam-
mation and immunity, we want to draw attention to another
still poorly studied dimension of cytokines, that is their role
in the central nervous system (CNS). The Cytokines in fact
are relevant for several ‘‘functions’’ in CNS, since they have
been implicated in neuronal differentiation and migration, in
acute and chronic neurodegenerative processes, in modifica-
tion of the synaptic plasticity and in affecting and regulating
the metabolism of neurotransmitters. Thus either considering
a dysregulation of Cytokines as an etiopathogenetic factor
for a given disease, or on the contrary their use as therapeutic
agents as for IFN-b in MS, we should be aware of a potential
effect as modulators of CNS functions.
The complexity and the current limited knowledge of the
different mechanisms of action of interferon therapy in MS pa-
thology suggest us that pharmacogenetics studies on MS needs
to be performed through large-scale genome screening and/or
large-scale expression studies as well as through interaction
modeling and pathway analyses to take into account all the
hypothetical genes and proteins potentially involved in the
process.
3. Clinical phenotype
Despite a tremendous technological improvement of phar-
macogenetics in the last years, it is remarkable how small
has been the methodological contribution to define the efficacy
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study design for pharmacogenetic studies.
We want to add our point of view to partially fill this gap by
addressing also a few clinically relevant issues.
3.1. Definition of drug-responder
We can distinguish two different aims of pharmacogenetic
studies: the identification of the polymorphisms associated
with the development of adverse events to a given drug, and
of the polymorphisms associated with an efficacy of the drug.
The definition of adverse event, especially if serious or life
threatening, is usually consistent and similar across studies.
On the contrary, there is more discrepancy on the definition
of what is meant for the efficacy of a given drug, and the ways
to measure efficacy clearly varied across different trials.
How did investigations address this issue in MS?
It is well known that inMS there are some disease-modifying
drugs, such as IFN, with partial efficacy estimated around 30%
of reduction of clinical relapses and around 70% of reduction
of magnetic resonance activity [3].
As shown in Table 1, the definition of ‘‘responder’’ is highly
variable across studies, sometimes based on clinical criteria,
and sometimes on clinical and Magnetic Resonance Imaging
(MRI) criteria. MRI are more sensitive than clinical criteria,
but we know that there is a low concordance between MRI
and clinical data, especially in relationship to the progression
of disability, leading to the so-called clinical-MRI paradox[12]. Consequently, MRI can be considered as a surrogate out-
come measure, but should not be used instead of clinical criteria
[13]. The papers by Trojano [14], Levya [4], Villoslada [15] and
Waubant [16] used only clinical criteria, while Sturzebecher
[17], Petzold [18], and Rudick [19] used a combination of clin-
ical and MRI criteria. More specifically, Waubant [16] studied
337 patients enrolled in the Lyon European Database for Mul-
tiple Sclerosis (EDMUS), and defined responders those who
have shown a reduction of the relapse rate on IFN-b (taken
for at least 6 months) compared to the previous 1 and 2 years.
Trojano [14] and Levya [4] too used clinical criteria to define
the efficacy of the drug, but they defined their patients as res-
ponders and non-responders based on the reduction of relapse
rate and disability progression, however classified in different
ways. Villoslada [15] mentioned two different types of criteria,
a first more stringent, defined as an absence of relapses and
a stable Expanded Disability Status Scale (EDSS) [20], and a
second less stringent, defined as a reduction of at least one
third of relapse rate. Sturzebecher [17] gave a definition of
drug-responder using a combination of clinical, namely a clini-
cally stable disease, and MRI criteria, using a previous defini-
tion from Stone [21]. In another paper [19], Rudick applied
a logistic regression model and ROC curves in a cohort of pa-
tients enrolled in a placebo-controlled clinical trial of IFN-b1a
to select the best predictors of drug responsiveness, which were
identified as absence of enhancing lesions (criteria 1), less
than 2 new T2 lesions developed (criteria 2), or no relapses
(criteria 3).Table 1
Definition of responders across different studies
Study Number of
patients
Responders definition:
MRI criteria
Responders definition: clinical
criteria e relapse rate (R-R)
Responders definition:
clinical criteria e
progression of disability
Proportion of responders
Sturzebecher
2003 [17]
10 O60% decrease
of gd-enhancing
lesions C
‘‘Stable disease’’ 60%
Waubant
2003 [16]
337 (IFN for
at least
6 months)
Lower R-R than 1 or
2 years before treatment
69% (RR); 68% (SP
with relapses)
Rudick 2004 [19] 172 Criteria 2: No
gd-enhancing lesions
in year 1 and 2.
Criteria. 3: %2 new
T2 lesions at year
2 vs. baseline
Criteria 1: No relapse
in 2 years
Criteria 1: 68%. Criteria 2:
75%. Criteria 3: 75%.
Petzold 2004 [18] 30 No gd-lesion (when
available) C
!2 relapses C EDSS stable or
increased %0.5 points
63%
Trojano 2003 [14] 540 (1-year
f-up); 378
(2-year f-up)
Criteria 1: No relapses Criteria 2: No sustained
and confirmed increase
of R1 EDSS score
Criteria 1: 50% (year 1);
30% (year 2). Criteria 2:
96 % (year 1); 90 %
(year 2)
Villoslada 2004 [15] 202 (IFN for
2 years)
Criteria 1: No relapse
Criteria 2: Decrease
of R-R O30%
versus 2 years
before treatment
Criteria 1: No increase
of EDSS
Not reported
Levya 2005 [4] 147 R-R equal or lower
than before
treatment C
No increase of EDSS after
the first year of treatment
70.7%
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patient, associated with the lack of rigorous and consistent
clinical/MRI criteria introduce a high degree of inconsisten-
cies across the various studies making any direct comparison
impossible, and at the same time increases the importance
and utility of surrogate markers, such as some hematological
markers, able to measure the therapeutic response. For exam-
ple, there are interesting data on the assessment and titer of
autoantibodies against interferons [22e24], which is higher
across poor and non-responder patients, but still their predic-
tive utility is not strong enough, thus requiring for new
markers of clinical efficacy.
A consistent and reproducible definition of drug efficacy
and ‘‘responder’’ across studies is extremely important for
study design and the interpretation of data. As a matter of
fact, the dimension of the sample is estimated on the expected
proportion of variability explained by certain gene polymor-
phisms, thus depending on the definition of responder, and
the statistical results can substantially differ if the definition
of outcome measures changes. Therefore, a consensus on the
best definition of treatment response is an absolute need.
Moreover, the efficacy of the drug, or the definition of res-
ponders, has to be decided before, instead of after, the plan-
ning of a pharmacogenetic study, to avoid post-hoc analyses
and ‘‘fishing’’ expeditions, without controlling for multiple
testing. The existence of clearly defined criteria would surely
help to solve even this problem.
3.2. Outcome measure for drug efficacy
Every drug can have different targets, and its efficacy can
be measured using different outcome measures.
There are clear-cut outcome measures, such as death,
against which the treatment is given to patients. However, in
most of the situations the target of the drug is different. In
MS, among the clinical and MRI outcomes used to study the
disease, the relapse rate and the number of enhancing lesions
reflect the inflammatory component of MS, while the disabil-
ity progression, as assessed with the EDSS and the number of
new T2 lesions, partially reflects the neurodegenerative com-
ponent of MS.
To further increase the complexity of the disease, the rela-
tionship between the inflammatory and the neurodegenerative
component is not clear; as a consequence, a drug able to
reduce the relapse rate does not always reduce the disability
progression. The neurodegenerative component is considered
the primary determinant of the neurological deficits in MS
patients and therefore, testing the efficacy of a drug by its
efficacy in reducing the progression of disability seems more
appropriate, using a consensus definition of a sustained and
confirmed worsening equal to at least 1.0 point if the baseline
EDSS is lower than 5.5 and of 0.5 if the EDSS is equal or
greater than 5.5. However, the progression of disability is dif-
ficult to measure in the short time, as it needs to be confirmed
at 3 or 6 months, and it is also poorly sensitive. Moreover,
there are limitations related to the EDSS scale, which meas-
ures a mixture of impairment and disability and is stronglyweighted towards locomotor disability and poorly related to
upper limb deficits and cognitive problems.
3.3. Study design
Most of the pharmacogenetic investigations are designed as
retrospective case-control rather than prospective follow-up
studies. However, a prospective design allows not only to bet-
ter evaluate the efficacy of the drug, but also to better define
the potential risk factors that should be identified and exam-
ined before beginning the specific pharmacogenetic study.
Moreover, prospective studies might allow the adjustments
of doses or the switch to a different immunomodulant drug
as a function of the genotype.
In conclusion, a pharmacogenetic study of MS is not an
easy task, as expected, but a simple and careful consideration
of few key points can help improving the quality of the inves-
tigation. First and foremost, it is essential to establish consis-
tent criteria that define the efficacy of the drug: for example,
we can categorize two different levels of responders, in agree-
ment with Villoslada [15], namely full responders (no relapses
and no confirmed disability progression when on-treatment)
and partial responder (reduction of relapse rate of one third
compared with the previous 2 years) contrasted to non-res-
ponders (O2 relapses or confirmed disability progression).
MRI criteria can be used, but as a surrogate secondary and
not as a primary outcome measure. The correct follow-up
should be a minimum of 2 years of treatment, and it is highly
warranted to perform studies on an intention-to-treat basis,
which could take into account also patients who interrupted
the treatment because of different reasons (such as adverse
events), avoiding selection bias.
Second, it should always be remembered that the definition of
responder must be established before the beginning of the study,
since a lot of critical parameters of the study itself, like the esti-
mation of the required sample size, are depending upon such
a definition Third, a proper causal relationship between the
administration of a drug and a relevant clinical outcome can
be recognized only with a prospective follow-up design.
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